Asia Pacific Polio Vaccine Market Size To Worth USD 572.25 Million By 2033 | CAGR of 4.07%
Category: HealthcareAsia Pacific Polio Vaccine Market Size To Worth USD 572.25 Million By 2033
According to a research report published by Spherical Insights & Consulting, the Asia Pacific Polio Vaccine Market Size is to Grow from USD 384.17 Million in 2023 to USD 572.25 Million by 2033, at a Compound Annual Growth Rate (CAGR) of 4.07% during the projected period.
Get more details on this report -
Browse key industry insights spread across 240 pages with 120 Market data tables and figures & charts from the report on the "Asia Pacific Polio Vaccine Market Size, Share, and COVID-19 Impact Analysis, By Type (Inactivated Polio Vaccine (IPV) and Oral Polio Vaccine (OPV)), By Application (Public and Private), and Asia Pacific (China, Japan, India, Rest of APAC) Polio Vaccine Market Insights, Industry Trend, Forecasts to 2033." Get Detailed Report Description Here: https://www.sphericalinsights.com/reports/asia-pacific-polio-vaccine-market
Polio Vaccines are vaccines that are used to prevent poliomyelitis (polio). Poliomyelitis is a highly infectious viral disease where the polio virus attacks the nervous system of a human being, which causes serious life-threatening disabilities and paralysis in a matter of hours. This virus spreads through person-to-person contact. Two types are used for deactivated poliovirus given by mouth it is oral polio vaccine (OPV), and inactivated poliomyelitis vaccine (IPV) given by injection. The World Health Organization (WHO) recommends four doses of polio vaccine to all children first dose aged 2 months, 4 months, 6-18 months, and from 4 to 6 years be fully vaccinated against polio respectively. The government's supportive policies regarding the eradication of polio are the factors responsible for the polio vaccine market growth. There is a growing need for polio immunization due to two factors, population growth and an increase in births. The polio vaccine was so inexpensive, that everyone could get vaccinated against polio. The market is propelled by global eradication initiatives, increased public health awareness, and government immunization programs. However, the market's expansion is hampered by side effects such as fever, chills, pain, and soreness, among many other things.
The oral polio vaccine (OPV) segment is anticipated to hold the largest revenue share of the Asia Pacific polio vaccine market during the anticipated timeframe.
Based on the type, the Asia Pacific polio vaccine market is classified into inactivated polio vaccine (IPV) and oral polio vaccine (OPV). Among these, the oral polio vaccine (OPV) segment is anticipated to hold the largest revenue share of the Asia Pacific polio vaccine market during the anticipated timeframe. The oral polio vaccine strains aid in the development of antibodies that protect children from the poliovirus that occurs in the wild or naturally. Positive factors include the ease of use and accessibility, which have contributed to the expansion of the oral polio vaccination industry.
The public segment is anticipated to dominate the Asia Pacific polio vaccine market during the projected timeframe.
Based on the application, the Asia Pacific polio vaccine market is classified into public and private. Among these, the public segment is anticipated to dominate the Asia Pacific polio vaccine market during the projected timeframe. Governments and public groups in the Asia-Pacific area have played a significant role in efforts to eradicate polio through vaccine development. Governments and health organizations also place a high priority on surveillance and case monitoring for potential polio cases in order to quickly detect and limit any outbreaks.
Major vendors in the Asia Pacific Polio Vaccine Market include Biological E, GSK, Serum Institute, Bharat Biotech, Novartis International AG, Sinovac Biotech, Panacea Biotec Ltd, Merck & Co., Inc., Bio-Med (P) Limited, and Others
Recent Developments
- In July 2024, to help prevent circulating vaccine-derived poliovirus type 2 (cVDPV2) outbreaks, Biological E, an Indian pharmaceutical and vaccine business, recently announced that the World Health Organization had prequalified its innovative oral poliovirus type 2 (nOPV2) vaccine.
Key Target Audience
- Market Players
- Investors
- End-users
- Government Authorities
- Consulting And Research Firm
- Venture capitalists
- Value-Added Resellers (VARs)
Market Segment
This study forecasts revenue at Asia Pacific, regional, and country levels from 2020 to 2033. Spherical Insights has segmented the Asia Pacific Polio Vaccine Market based on the below-mentioned segments:
Asia Pacific Polio Vaccine Market, By Type
- Inactivated polio vaccine (IPV)
- Oral polio vaccine (OPV)
Asia Pacific Polio Vaccine Market, By Application
- Public
- Private
Asia Pacific Polio Vaccine Market, By Country
- China
- Japan
- South Korea
- Australia
- Rest of the APAC
About the Spherical Insights & Consulting
Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.
Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements.
CONTACT US:
For More Information on Your Target Market, Please Contact Us Below:
Phone: +1 303 800 4326 (the U.S.)
Phone: +91 90289 24100 (APAC)
Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com
Contact Us: https://www.sphericalinsights.com/contact-us
Need help to buy this report?